LAG3 expression

Nivolumab & relatlimab demonstrated clinical benefit w/ a manageable safety profile in pts w/ advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression. @evanlipson @hopkinskimmel #melsm https://t.co/K7sJD0Bhlq (@OncLive)

Nivolumab & relatlimab demonstrated clinical benefit w/ a manageable safety profile in pts w/ advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression. @evanlipson @hopkinskimmel #melsm https://t.co/yG5OlPCryK (@OncLive)

So proud of research team @MelanomaAus presenting at @SocietyMelanoma congress on spatial analysis and expression LAG3 in advanced #melanoma. @inespiresilva @ProfRScolyerMIA (@ProfGLongMIA)

@DrChoueiri on translocation-associated RCC @bmuc_be : more LAG-3 expression >> therapeutic agent? (@msaerens01)

Novel pred biomarkers of response to ICB w/ Nivo ± Ipi in TITAN-RCC ph 2 trial 📌Nivo induction: ⬆️ 4-1BB- or LAG-3 expressing T cells ➡️ Rx response 📌Nivo + Ipi “boosts”: ⬆️ PD-L1-expressing myeloid cells & plasmacytoid dendritic cell ➡️ better prog @urotoday #GU22 Rapid Abst (@zklaassen_md)

Could concomitant type 2 diabetes influence response to checkpoint inhibition in metastatic melanoma? A potential role for Lag-3 expression is reported in this Letter to the Editor by @PAscierto and coll. https://t.co/FoLSGve0SQ #melsm (@Annals_Oncology)

RELATIVITY-047 (Nivo + relatlimab anti-LAG3) is (+) for PFS #melanoma! 1st validated checkpoint beyond PD1/CTLA4. Can't wait to see breakdown by PDL1 & LAG3 expression. Where ipi-nivo works best in PDL1 lo, my guess is this works best in PDL1 hi. Biomarker time in #immunotherapy! (@jasonlukemd)